医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

R-Tech Ueno Received Orphan Drug Designation for Unoprostone Isopropyl (Development Code:UF-021) for the Treatment of Retinitis Pigmentosa from MHLW

2014年11月25日 PM12:20
このエントリーをはてなブックマークに追加


 

TOKYO

R-Tech Ueno (JASDAQ:4573):

R-Tech Ueno, Ltd. today announced that we have officially received the Orphan Drug Designation from the Ministry of Health, Labour and Welfare (MHLW) for Unoprostone Isopropyl (Unoprostone) (development code : UF-021) for the treatment of retinitis pigmentosa.

Drugs and biologics with orphan drug designation in Japan are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 50,000 patients (maximal incidence of four per ten thousand), with incentives for sponsors to develop orphan products such as priority review of New Drug Applications (NDAs) by the Pharmaceuticals and Medical Devices Agency (PMDA), and grant funding for sponsors.

We are developing a therapeutic agent for treatment of retinitis pigmentosa with unoprostone as the main ingredient and are conducting a phase 3 clinical trial of the ophthalmic solution with unoprostone (development code: UF-021) as the main ingredient (press release of March 13, 2013). A phase 2 clinical trial indicated that the number of patients whose retina sensitivity in the central retina deteriorated was reduced (press releases of June 3 and July 15, 2010). The development of retinitis pigmentosa treatment by unoprostone in Japan has support from government and was adopted in the Adaptable and Seamless Technology Program through Target-Driven R&D (A-STEP) as “Full-scale R&D Stage – Practical Application Type (Contract Development)” by the Japan Science and Technology Agency (JST) (press release of February 1, 2013). We are further increasing our efforts for early approval of this drug.

We licensed the overseas development and commercialization rights for unoprostone to Sucampo Pharmaceuticals, Inc. (Sucampo), for the United States and Canada in 2009, and then for the United States, Canada and the rest of the world excluding our own territories (Japan, South Korea, Taiwan and China) in 2011. While we retain the exclusive rights to manufacture and supply unoprostone products in our territory, we have an efficient partnership with Sucampo for overseas development of unoprostone.

Unoprostone has been designated as an orphan drug for the treatment of retinitis pigmentosa not only by the FDA in the United States but also by the EMA in the European Union, and R-Tech Ueno’s development partner, Sucampo will decide on their path forward assuming our Phase 3 trial is successful.

The above venture will not contribute to any revision of the full-year earnings estimates pre-announced on May 14, 2014.

For full details of the press release, please visit:
http://www.rtechueno.com/en/investor/press/documents/141125_pr_en.pdf

CONTACT

R-Tech Ueno, Ltd.
Koji Nakamura, +81-3-3596-8011
Director
Business
Management Department
info@rtueno.co.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • レスメド後援の研究で在宅酸素療法と在宅非侵襲的換気療法の併用が費用対効果の高いCOPD治療法であると判明
  • Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
  • Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
  • 继美国和英国之后,中国向Personalis, Inc.签发ACE©技术专利,扩大了其在国际上的知名度
  • セルヴォー・テクノロジーズが日本の東京都健康長寿医療センター研究所と研究契約を締結